In May 2022, the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA) announced the launch of a new program for expediting the development of.
In May 2022, the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA) announced the launch of a new program for expediting the development of new treatment options for rare diseases Accelerating Rare disease Cures (ARC) Program.1 The FDA considers a disease that affects fewer than 200,000 people in the U.S. a rare disease, and estimates that more than 30…